Epidemiology & Risk Factors

  • Pathogen: Cryptosporidium parvum or C. hominis (intracellular protozoa).
  • Transmission: Fecal-oral ingestion of chlorine-resistant oocysts via contaminated water (swimming pools, municipal supply), daycare exposure, or animal contact. c
  • Risk Factors:
    • Immunocompromised state: HIV/AIDS w/ CD4 < 100/mm³, solid organ transplant, congenital T-cell immunodeficiencies.
    • Immunocompetent: Travelers, pool users, daycare workers. c

Clinical Features

  • Immunocompetent:
    • Self-limiting profuse, watery, non-bloody diarrhea.
    • Crampy abdominal pain, low-grade fever, nausea, anorexia (resolves in 1–2 weeks).
  • Immunocompromised (HIV w/ CD4 < 100/mm³):
    • Chronic, intractable, severe secretory diarrhea (> 2–3 L/day).
    • Malabsorption, profound weight loss, severe electrolyte wasting, dehydration.

Diagnosis

  • Initial/Key Test: Stool examination with modified acid-fast stain revealing pink/red oocysts (4–6 µm).
  • Confirmatory/High-Sensitivity Tests:
    • Stool PCR assay (multiplex GI panel).
    • Stool immunoassay (EIA/ELISA) for Cryptosporidium antigen.
  • Biopsy (Rarely needed): Intracellular organisms lining the brush border of intestinal epithelial cells.

Differential Diagnostics

  • Cystoisospora belli: Diff by larger, oval-shaped oocysts on modified acid-fast stain; treat w/ TMP-SMX.
  • Microsporidia: Diff by smaller spores (1–2 µm), non-acid-fast (requires chromotrope 2R/calcofluor white stain); treat w/ Albendazole.
  • Giardia lamblia: Diff by flagellated pear-shaped trophozoites with 2 nuclei; presents w/ severe bloating, foul-smelling flatus, steatorrhea; treat w/ Metronidazole.
  • CMV Colitis: Diff by bloody diarrhea, CD4 < 50, mucosal ulceration, colonoscopy biopsy w/ intranuclear inclusion bodies (“owl’s eye”); treat w/ Ganciclovir.
  • Mycobacterium avium complex (MAC): Diff by CD4 < 50, high fevers, night sweats, hepatosplenomegaly, watery diarrhea; treat w/ Azithromycin + Ethambutol.

Management

  1. Immunocompetent:
    • Supportive: Fluid and electrolyte replacement.
    • Persistent/Severe: Nitazoxanide (orally for 3 days).
  2. Immunocompromised (HIV/AIDS):
    • Primary/Most Effective Tx: Antiretroviral Therapy (ART) to restore immune function (CD4 > 100/mm³ drives clearance).
    • Symptomatic/Adjunctive: Nitazoxanide (decreased efficacy without immune reconstitution).
    • Supportive: Aggressive IV hydration, antidiarrheals (e.g., loperamide, octreotide if refractory).

Complications

  • Severe hypovolemic shock & acute kidney injury (AKI) from dehydration.
  • AIDS Cholangiopathy: Acquired sclerosing cholangitis or acalculous cholecystitis (presents w/ RUQ pain, ↑ ALP).
  • Failure to thrive and severe malnutrition/wasting in chronic cases.